Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

Article summary

Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8 ® for the treatment of amyotrophic lateral sclerosis (ALS).